(Q50501119)

14 March 2018

title

Hemolytic anemia due to passenger lymphocyte syndrome in solid malignancy patients treated with allogeneic natural killer cell products. (English)

1 reference

14 March 2018

1 reference

8

1 reference

14 March 2018

Sarah R. Cooley

3

object named as

Sarah Cooley

1 reference

14 March 2018

author name string

Robert Skeate

1

1 reference

14 March 2018

Charanjeet Singh

2

1 reference

14 March 2018

Melissa Geller

4

1 reference

14 March 2018

Joan Northouse

5

1 reference

14 March 2018

Julie Welbig

6

1 reference

14 March 2018

Arne Slungaard

7

1 reference

14 March 2018

David McKenna

9

1 reference

14 March 2018

publication date

1 November 2012

1 reference

14 March 2018

published in

Transfusion

1 reference

14 March 2018

volume

53

1 reference

14 March 2018

issue

2

1 reference

14 March 2018

page(s)

419-423

1 reference

14 March 2018

Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03942.X

Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03942.X

Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03942.X

Immune hemolysis associated with transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03942.X

Immune hemolysis following ABO-mismatched stem cell or solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03942.X

Hematologic disorders after solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03942.X

A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03942.X

Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03942.X

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2012.03942.X

10.1111/J.1537-2995.2012.03942.X

21 January 2018

Identifiers

DOI

1 reference

14 March 2018

1 reference

14 March 2018